Atrion (NASDAQ:ATRI) and Neovasc (NASDAQ:NVCN) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, earnings, dividends and analyst recommendations.

Profitability

This table compares Atrion and Neovasc’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Atrion 22.76% 16.89% 15.30%
Neovasc -2,977.34% N/A -165.43%

Earnings and Valuation

This table compares Atrion and Neovasc’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Atrion $152.45 million 9.83 $34.26 million N/A N/A
Neovasc $1.75 million 20.39 -$108.04 million ($27.30) -0.17

Atrion has higher revenue and earnings than Neovasc.

Dividends

Atrion pays an annual dividend of $5.40 per share and has a dividend yield of 0.7%. Neovasc does not pay a dividend. Atrion has raised its dividend for 16 consecutive years.

Insider and Institutional Ownership

62.6% of Atrion shares are held by institutional investors. Comparatively, 10.0% of Neovasc shares are held by institutional investors. 22.1% of Atrion shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Atrion and Neovasc, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Atrion 0 0 0 0 N/A
Neovasc 0 0 0 0 N/A

Risk and Volatility

Atrion has a beta of 0.33, indicating that its share price is 67% less volatile than the S&P 500. Comparatively, Neovasc has a beta of 1.43, indicating that its share price is 43% more volatile than the S&P 500.

Summary

Atrion beats Neovasc on 10 of the 12 factors compared between the two stocks.

About Atrion

Atrion Corporation develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmology applications worldwide. Its fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments. The company's cardiovascular products comprise MPS2 Myocardial Protection System that delivers fluids and medications, mixes critical drugs, and controls temperature, pressure, and other variables; cardiac surgery vacuum relief valves; silicone vessel loops for retracting and occluding vessels; and inflation devices for balloon catheter dilation, stent deployment, and fluid dispensing, as well as products for use in heart bypass surgery. Its ophthalmic products include specialized medical devices that disinfect contact lenses; and a line of balloon catheters, which are used for the treatment of nasolacrimal duct obstruction in children and adults. The company also manufactures instrumentation and associated disposables that measures the activated clotting time of blood; and a line of products designed for safe needle and scalpel blade containment. In addition, it manufactures inflation systems and valves used in marine and aviation safety products; components used in inflatable survival products and structures; one-way and two-way pressure relief valves that protect sensitive electronics; and other products during transport in other medical and non-medical applications. The company sells its products to physicians, hospitals, clinics, and other treatment centers; and other equipment manufacturers through direct sales personnel, independent sales representatives, and distributors. Atrion Corporation was founded in 1944 and is headquartered in Allen, Texas.

About Neovasc

Neovasc Inc., a specialty medical device company, develops, manufactures, and markets cardiovascular devices worldwide. Its products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. The company also provides Peripatch tissue products. The company was formerly known as Medical Ventures Corp. and changed its name to Neovasc Inc. in July 2008. Neovasc Inc. was incorporated in 2000 and is headquartered in Richmond, Canada.

Receive News & Ratings for Atrion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion and related companies with MarketBeat.com's FREE daily email newsletter.